Growth Hormone Treatment in Adult Patients With Chronic Kidney Disease

Phase 2

Completed

• Conditions: End-Stage Renal Disease; Chronic Kidney Disease

• Registration Number: NCT00184652
• Lead Sponsor: Novo Nordisk A/S

Brief Summary

This trial is conducted in Asia, Europe, and Middle East. Adult patients with chronic kidney disease are treated with growth hormone to assess effect on nutritional status.

Detailed Description

Not available

Study Timeline

• Study Start: 2003-04
• Primary Completion: 2005-09
• Study Completion: 2005-09
• Study First Submitted: 2005-09-13
• Study First Submitted QC: 2005-09-13
• Study First Posted: 2005-09-16
• Status Verified: 2017-01
• Last Update Submitted: 2017-01-23
• Last Update Posted: 2017-01-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 140

Inclusion Criteria

• ESRD patients

Exclusion Criteria

• Diabetes Mellitus
• Severe and Malignant diseases
• Patients in Intensive Care Units

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Change in surrogate markers of nutrition	After 6 months treatment

Secondary Outcome Measures

Name	Time	Method
Quality of Life
Other markers of nutrition

Trial Locations

Locations (1)

Novo Nordisk Investigational Site; 🇬🇧 Swansea, United Kingdom